Monopar highlights neurologic Phase 3 data for ALXN1840
Bottom line
Monopar Therapeutics said new Phase 3 FoCus analyses of ALXN1840 in Wilson disease showed greater neurologic benefit than standard of care in patients who had neurologic symptoms at baseline, with the data presented at the American Academy of Neurology’s 2026 annual meeting. In that subgroup, clinically meaningful neurologic worsening at 48 weeks was reported in 9% of ALXN1840-treated patients versus 25% with standard care, while clinically meaningful improvement was seen in 45% versus 32%, respectively. Monopar licensed ALXN1840 from Alexion, AstraZeneca Rare Disease in October 2024, and the company now says, based on recent FDA interactions, it plans to submit a New Drug Application in mid-2026. (biospace.com)
Why it matters: Wilson disease is a rare human genetic disorder marked by toxic copper buildup in the liver and brain, and Monopar is positioning ALXN1840 as a differentiated, once-daily oral option with a copper-mobilizing mechanism distinct from currently available first-line therapies. For veterinary professionals, the direct clinical relevance is limited because this is a human rare-disease program, but the story is still useful as a marker of broader translational interest in copper metabolism, neurologic outcomes, and long-term chelation-style treatment strategies. The company has also highlighted prior Journal of Hepatology publication activity and patient-focused FDA discussions as part of its regulatory package-building effort. (ir.monopartx.com)
What to watch: The next key milestone is whether Monopar files its NDA for ALXN1840 with the FDA in mid-2026, and whether regulators view the neurologic subgroup and long-term data as sufficient to support approval. (ir.monopartx.com)
Monopar Therapeutics is using fresh Phase 3 FoCus data to strengthen the case for ALXN1840 in Wilson disease, reporting at AAN 2026 that the investigational therapy delivered greater neurologic benefit than standard of care in patients who entered the study with neurologic symptoms. The company said the new analysis showed both less clinically meaningful worsening and more improvement through 48 weeks, adding a potentially important layer to a program already built around positive copper-mobilization data. (biospace.com)
The backdrop here goes back well before Monopar took control of the asset. Alexion had already advanced ALXN1840 through a Phase 3 trial that Monopar says met its primary endpoint, and Monopar acquired exclusive worldwide rights in October 2024. Since then, the company has been assembling a broader narrative around the drug, including long-term efficacy and safety presentations, a Journal of Hepatology letter on copper balance, and patient-focused regulatory engagement with the FDA. (ir.monopartx.com)
The latest data presentation focused on neurologic Wilson disease, a clinically important subgroup because neurologic deterioration during treatment initiation has been a longstanding concern in this disease area. According to Monopar’s AAN presentation summary, among patients with neurologic symptoms at baseline, clinically meaningful neurologic worsening at week 48 occurred in 25% of patients on standard of care and 9% of patients treated with ALXN1840. Clinically meaningful neurologic improvement was reported in 45% of the ALXN1840 group versus 32% with standard care, and Clinical Global Impression-Improvement results also favored ALXN1840, 47% versus 19%. The company further said neurologic benefit was sustained over roughly three years of follow-up in treated patients. (biospace.com)
Those findings build on the original FoCus readout that Monopar has continued to cite in investor and regulatory materials. In describing the asset after the Alexion deal, the company said the Phase 3 study met its primary endpoint, showing three-times greater copper mobilization from tissues versus standard of care, with response evident by four weeks and sustained through 48 weeks. Monopar has also said ALXN1840 was generally well tolerated in the trial, with most adverse events mild to moderate, and that reversible transaminase increases were the most frequently reported adverse event in the treatment arm. (ir.monopartx.com)
Independent expert reaction to the new AAN dataset was limited in publicly available sources at the time of writing, but Monopar’s presenters and collaborating physicians have consistently emphasized two themes: rapid control of copper balance and the importance of neurologic outcomes. The company previously announced that a physicians’ letter published in the Journal of Hepatology described rapid and sustained improvement in daily copper balance, driven mainly by increased fecal copper excretion. Separately, the Wilson Disease Association’s January 29, 2026 externally led patient-focused drug development meeting underscored the burden of current treatment options and the demand for additional therapies, giving Monopar a clearer patient-experience backdrop as it heads toward filing. (ir.monopartx.com)
Why it matters: For veterinary professionals, this is not a practice-changing animal health story, but it is relevant as a window into how copper dysregulation is being targeted in human medicine, especially where hepatic and neurologic injury intersect. Copper-associated hepatopathies are a familiar concept in veterinary medicine, even though Wilson disease itself is a human inherited disorder. The ALXN1840 story is also a reminder that regulators and clinicians are looking beyond biochemical markers alone: durability, neurologic function, tolerability, and patient-reported burden are all shaping the value proposition. That broader framework may resonate with veterinary teams managing chronic liver disease, counseling pet parents through long treatment courses, or tracking translational developments in metal metabolism. (ir.monopartx.com)
There’s also a business and regulatory angle. In March 2026, Monopar told investors that, following recent FDA interactions, it had shifted its planned NDA submission timing to mid-2026. The company has been building commercial leadership ahead of that milestone, suggesting it sees a realistic path toward launch if the application is accepted and reviewed favorably. (ir.monopartx.com)
What to watch: The next inflection point is the NDA submission itself, expected in mid-2026, followed by any FDA commentary on the adequacy of the neurologic subgroup analysis, long-term safety package, and overall benefit-risk profile. If accepted, ALXN1840 could become one of the most closely watched rare-disease liver and neurology filings of the year. (ir.monopartx.com)